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Clostridioides difficile is an opportunistic enteric pathogen that can cause a range of 
symptoms in humans from diarrhea to pseudomembranous colitis. The risk of recurrence of C. 
difficile infection after initial treatment with antibiotics is high. Although prior studies have 
sought to understand the link between the human gut microbiome and the risk of recurrence, 
none have utilized shotgun metagenomic sequencing methods to establish a relationship between 
microbiota diversity and recurrence risk. In this study, stool samples were obtained from 47 
patients at Yale New Haven Hospital who tested positive for an incident C. difficile infection. 
Shotgun metagenomic sequencing was used to characterize the abundance and diversity of the 
microbiota and the antibiotic resistome of each sample. The association between taxonomic 
diversity of the gastrointestinal microbiota and the risk for recurrence, case definition, and 
patient characteristics was analyzed. There was a significant association between age and the risk 
for recurrent infection, with older patients more likely to experience recurrence. Linear 
discriminant analysis effect size revealed that certain taxonomic groups were differentially 
prevalent in patients with and without a recurrent episode and in patients with community-
acquired infections vs. those with hospital- or healthcare-associated infections. Those who 
experienced a recurrent infection had a higher abundance of Blautia producta, and a lower of 
abundance of Gardnerella vaginalis and Eggerthella lenta than patients who did not experience 
a recurrence. The microbiota of patients who had a community-acquired infection were more 
likely to include protective bacterial species and bacteriophage, such as Bacteroides, 
Faecalibacterium prausnitzii, and crAssphage. This study provides a preliminary exploration 
into the association between the human microbiome and the risk of C. difficile recurrence and 
demonstrates the value of using shotgun metagenomic sequencing for further investigation.  
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Tables and Figures 
 
Table 1. Description of the sample, by CDI recurrence.a 
  Recurrence   
Characteristic Yes (N = 7) No (N = 35) pb 
Age (years) 75.1 ± 12.9 54.9 ± 24.1 0.03 
Sex    
  Male 3 (42.9) 17 (48.6) 1.00 
  Female 4 (57.1) 18 (51.4)  
Case Definition   0.73 
   Hospital-acquired 2 (28.6) 11 (31.4)  
   Healthcare- associated 5 (71.4) 18 (51.4)  
   Community-acquired 0 (0.0) 5 (17.1)  
Chronic Kidney Disease   0.16 
   Yes 3 (42.9) 6 (17.1)  
   No 4 (57.1) 29 (82.7)  
Congestive Heart Failure   0.19 
   Yes 2 (28.6) 3 (8.6)  
    No 5 (71.4) 32 (91.4)  
Stroke   0.53 
   Yes  1 (14.3) 3 (8.6)  
    No 6 (85.7) 32 (91.4)  
Diabetes mellitus   0.11 
   Yes  3 (42.9) 5 (14.3)  
   No 4 (57.1) 30 (85.7)  
Antibiotic use ≤ 12 weeks before 
incident CDI   1.00 
   Yes 6 (85.7) 28 (80.0)  
   No 1 (14.3) 5 (14.3)  
   Unknown 0 (0.0) 2 (5.7)  
H2 blocker use ≤ 12 weeks 
before incident CDI   1.00 
   Yes 3 (42.9) 17 (48.6)  
   No 4 (57.1) 17 (48.6)  
   Unknown 0 (0.0) 1 (2.9)  
Proton pump inhibitor use ≤ 12 
weeks before incident CDI   0.53 
   Yes 2 (28.6) 16 (45.7)  
   No 5 (71.4) 18 (51.4)  
   Unknown 0 (0.0) 1 (2.9)  
a Table values are mean ± SD for continuous variable and n (column %) for categorical variables. 




Figure 1. Heatmap of the most abundant antibiotic resistance genes in stool samples from 42 patients. The color 

















































Figure 2. Linear discriminant analysis effect size scores for comparisons between relative abundance of antibiotic 
resistance genes among 47 patients based on case definition. A. Hospital-acquired infections vs. community-
acquired infections. B. Healthcare-associated infections vs. community-acquired infections. Abbreviation: LDA, 








































Figure 3. Linear discriminant analysis effect size scores for comparisons between relative abundance of taxa among 






































































Figure 4. Linear discriminant analysis effect size scores for comparisons between relative abundance of taxa among 
47 patients based on case definition. A. Hospital-acquired infections (1) vs. healthcare-associated infections (2). B. 
Hospital-acquired infections (1) vs. community-acquired infections (3). C. Healthcare-associated infections (2, not 










Clostridioides difficile is a gram-positive, spore-forming bacillus that causes diarrhea and 
colitis in susceptible individuals. It is a major cause of healthcare-associated infections in the 
United States, with upwards of half a million infections and nearly 30,000 associated deaths 
every year.1 Up to 20% of all individuals who are infected with C. difficile experience a 
recurrence in infection within twelve weeks of treatment.2 As such, C. difficile places a large 
burden on the US healthcare system, costing nearly $1.5 billion total annually.3 Although 
initially considered to be a primarily nosocomial or healthcare-associated infection, community-
acquired C. difficile infections (CDIs) have become an increasing problem, especially among 
populations previously thought to be at low risk for infection.4 
 C. difficile is resistant to a wide array of commonly used antibiotics, including penicillin, 
cephalosporins, clindamycin, tetracyclines, and fluoroquinolones.5 Thus, it is an opportunistic 
pathogen that takes advantage of disturbances in the normal human gut microflora to proliferate 
and cause disease in human hosts.6 One of the major risk factors for CDI, therefore, is repeated 
or sustained antibiotic usage.7 Other known risk factors for infection are overnight stays in 
hospitals and long-term care facilities, advanced age, underlying medical problems, reduction of 
stomach acid through proton pump inhibitors, and the use of immunosuppressants.8-10 The risk 
factors for recurrent infection are similar to that of incident infection and include increasing age 
and the severity of primary infection.11 
 Understanding the role of the gut microbiome in C. difficile infection is essential to 
understanding the risk factors for infection and developing targets for infection prevention and 
treatment. Certain bacterial species in the human gut microbiome have been shown to be 
associated with resistance to colonization by C. difficile, specifically members within 
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Ruminococcaceae, Lachnospiraceae, Bacteroides, and Porphyromonadaceae.12 Infection with C. 
difficile has also been associated with a higher abundance and lower diversity of bacteriophage 
Caudovirales.13 A metagenomic analysis of CDI-infected elderly patients in a hospital setting 
revealed that C. difficile infection was associated with a lower gut microbial diversity, as well as 
a lower incidence of commensal microbes and a higher incidence of opportunistic pathogens.14 
Furthermore, studies in infants suggest that a machine learning approach can be used to identify 
antibiotic resistance genes within the gut that can predict the effect of antibiotics on the gut 
microflora, a tool that could be utilized for predicting treatment outcomes for CDI.15       
 The association between the human gut microbiome and the risk of CDI recurrence has 
been explored using 16S rRNA gene sequencing. One such study found that patients who 
experienced a recurrent episode had elevated levels of Veillonella, Enterobacteriaceae, 
Streptococcus, Parabacteroides and Lachnospiraceae.16  Although the link between the human 
microbiome and CDI risk has been investigated in previous studies, shotgun metagenomic 
sequencing has not yet been used to determine the relationship between the human gut 
microbiome and antibiotic resistome and the risk for CDI recurrence. 
The goal of this study was to use shotgun metagenomic sequencing methods to determine 
the association between the risk of recurrence and the following factors: the abundance and 
diversity of specific bacterial taxa within the gut microbiome, and the presence of antibiotic 
resistance genes.  
Methods 
 
 Yale University’s institutional review board approved this study. Stool samples were 
obtained through collaboration with Connecticut’s Emerging Infections Program, which is 
responsible for C. difficile surveillance within the New Haven catchment area. From April 26, 
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2019 to December 19, 2019, a total of 47 stool samples were collected from patients at Yale New 
Haven Hospital who tested positive for an incident C. difficile infection. A case was defined as 
incident if the individual was not treated for CDI in the twelve weeks prior to the date of stool 
collection. A medical chart review was conducted for each individual to identify possible risk 
factors for infection, including past medical history, antibiotic use, use of proton pump 
inhibitors, H2 blockers, and other immunosuppressants, as well as details on CDI treatment and 
recent contact with healthcare.  
Individuals were classified based on recurrence status and case definition. A case was 
defined as recurrent if an individual experienced a second CDI within 2-12 weeks after incident 
infection. Any infection after this time period was considered a re-infection and not counted 
among the recurrent cases. Additionally, all CDIs included in the study were classified into one 
of three case definition groups: hospital-acquired infections, healthcare-associated community 
onset infections, and community-acquired infections. An infection was considered to be hospital-
acquired if the incident stool sample was collected at least 3 days after admission to a hospital. In 
contrast, an infection was considered to be healthcare-associated community onset if the incident 
stool sample was collected less than 3 days after admission to a hospital and/or the patient had 
any of the following encounters with health care within 12 weeks of the date of the incident stool 
sample collection: visited a hospital emergency department, received surgery or dialysis 
treatment, or was admitted to a hospital. A patient’s CDI was considered community-acquired if 
they did have any health care encounters within 12 weeks prior to the incident stool sample 
collection and/or their stool sample was collected less than 3 days after admission to a hospital. 
 Microbial DNA was extracted from stool samples using the PureLink Microbiome 
Purification Kit (Invitrogen). After DNA quantification using the Quant-iT Assay Kit 
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(Invitrogen), samples were prepared for sequencing using the NEBNext Ultra II FS DNA Library 
Prep Kit for Illumina (New England Biolabs). Shotgun metagenomic sequencing was carried out 
on an Illumina HiSeq4000 at the Yale Center for Genome Analysis, after which taxonomic 
identification of bacteria and bacteriophage was carried out. Taxonomic labels were assigned to 
DNA sequences using Kraken, and species abundance was estimated using Bracken.17,18 
Antibiotic resistance genes (ARGs) were identified and quantified using ARGs-OAP v2.0.19 
ARG copy numbers were normalized against reference sequence lengths and then against 
prokaryotic cell number, and were grouped into the following ARG types based on mechanism 
of resistance: aminoglycoside, bacitracin, beta-lactam, bleomycin, chloramphenicol, fosfomycin, 
fosmidomycin, kasugamycin, macrolide-lincosamide-streptogramin, polymyxin, quinolone, 
rifamycin, sulfonamide, tetracycline, trimethoprim, vancomycin, and multidrug.  
After the microbiome and antibiotic resistome for each sample were characterized, 
statistical methods were used to determine the unadjusted associations between case definition or 
the risk for recurrence and the following variables: age, sex at birth, underlying medical 
conditions, and the use of antibiotics, H2 blockers, and proton pump inhibitors prior to incident 
infection. Due to the low sample size, categorical variables were analyzed using Fisher’s Exact 
test. Age was analyzed using Duncan’s new multiple range test or one-way analysis of variance 
(ANOVA) as appropriate. All analyses were carried out using SAS v9.4.  
Linear discriminant analysis effect size (LefSe) was used to identify differences in the 
presence and abundance of antibiotic resistance genes in patients who experienced a recurrent 
episode and those who did not. LefSe was also used to compare differences between the three 
case definitions by analyzing each pair of categories separately: community-acquired vs. hospital 
acquired, community-acquired vs. healthcare-associated, and hospital-acquired vs. healthcare-
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associated. An alpha value of 0.1 and a threshold on the logarithmic linear discriminant analysis 
(LDA) score for discriminative features of 2.0 were used. 
LefSe was also used to compare the taxonomic diversity between patients with and 
without a recurrent episode and between case definitions. Before analysis, the proportion of total 
sequencing reads was recalculated for each species in each sample after the removal of human 
DNA. The proportion of sequencing reads for each taxonomic group was summed across all 
samples, and the top 65 taxa with the highest total relative abundance were selected for analysis. 
The combined dataset was restricted to these 65 species while the rest of the taxonomic groups 
were collapsed into a single category for each sample. An alpha value of 0.1 and the and a 
threshold on the LDA score for discriminative features of 2.0 were used. 
Results 
 
 A total of 47 stool samples were obtained for metagenomic analysis. Out of the 47 
individuals who provided a stool sample, 25 were male and 22 were female, with ages ranging 
from 3 to 95. Of the total, 16 infections were classified as hospital-acquired, 25 were classified 
as healthcare-associated community onset, and 6 were community-acquired. Five of the 
individuals in the study died before the period during which a recurrent C. difficile episode may 
have occurred. These subjects were excluded from all analyses that used recurrence as a 
dependent variable. The resulting sample of 42 individuals included 20 males and 22 females. Of 
this sample, 7 individuals experienced a recurrent episode 2-12 weeks after incident infection. 
The majority of individuals had underlying medical conditions prior to their incident C. 
difficile infections. The most common medical conditions were chronic kidney disease (n=11), 
diabetes mellitus (n=9), congestive heart failure (n=7), recent solid organ transplants (n=7), and 
hematologic malignancies (n=7). Frequency of medication use within 12 weeks of the incident 
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positive stool sample was also fairly high; 20 subjects took proton pump inhibitors, 21 took H2 
blockers, while 29 took some other type of immunosuppressive therapy, such as steroids and/or 
chemotherapy. Antimicrobial therapy within the 12 weeks of incident stool collection was 
extremely common; 39 individuals were prescribed at least one antibiotic during that time 
period. The most common antibiotics were piperacillin/tazobactam (n=13), vancomycin (n=12), 
ciprofloxacin (n=11), ceftriaxone (n=11), and metronidazole (n=8). Cephalosporins were the 
most commonly administered class of antibiotics (n=21), followed by penicillins (n=20), and 
fluoroquinolones (n=14).  
 Age was found to be significantly associated with the risk for recurrence. Older people 
were more likely to experience a recurrent episode than younger people (p=0.038; Table 1). No 
other significant associations were observed between recurrence and other exposures of interest, 
including case definition, comorbidities, antibiotic use, and H2 blocker and proton pump 
inhibitor use. There were also no significant associations between these variables and case 
definition. 
 Hierarchical clustering was used to group samples by the abundance of antibiotic 
resistance genes (Figure 1). Samples did not cluster based on recurrence or case definition. 
However, LefSe indicated that genes that conferred resistance to fosfomycin were more 
abundant in patients who experienced hospital-acquired infections compared to those who 
experienced a community-acquired infection (Figure 2a). Additionally, bacitracin and 
sulfonamide resistance genes were more abundant in healthcare-associated community-onset 
infections than in community-acquired infections (Figure 2b). There were no significant 
differences in the abundance of ARGs between hospital-acquired and healthcare-associated 
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infections. Similarly, no differences were observed in the abundance of ARGs between patients 
who did and did not experience a recurrent infection. 
 A total of 6059 bacterial taxa and bacteriophage were identified in stool samples from 47 
patients. LefSe identified certain taxa as differentially abundant depending on a patient’s 
recurrence status. Patients who experienced a recurrent infection had a higher abundance of 
Blautia producta and a lower of abundance of Gardnerella vaginalis and Eggerthella lenta than 
patients who did not experience a recurrence (Figure 3). Differences in taxonomic abundance 
were also observed between case definitions. Compared to healthcare-associated infections, 
hospital-acquired infections had a higher abundance of Actinomyces pacaensis, Veillonella 
dispar, and Streptococcus salivarius, and lower abundance of B. producta, Erysipelotrichaceae, 
and Enterococcus faecalis (Figure 4a). In comparison to community-acquired infections, 
hospital-acquired infections had a higher abundance of Bifidobacterium longum and Collinsella 
aerofasciens, and a lower abundance of Bacteroides vulgatus, Bacteroides fragilis, 
Faecalibacterium prausnitzii, Alistipes finegoldii, and crAssphage (Figure 4b). Finally, patients 
with community-acquired infections had a higher abundance of B. vulgatus, Bacteroides 
helcogenes, and B. fragilis than patients with healthcare-associated infections (Figure 4c).  
Discussion 
 
 The results from this study provide preliminary evidence that the risk of recurrence of C. 
difficile infection is associated with the diversity and composition of the human gut microbiome. 
Metagenomic analysis of stool samples from 42 patients suggests that B. producta is associated 
with the risk of recurrence. This finding is somewhat surprising because Blautia is a commensal 
genus that has been shown to be underrepresented in C. difficile-positive stool samples.20 In one 
study, B. producta was used with a cocktail of nine other bacterial species to successfully treat 
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chronic CDI in five patients.21 All of the patients in this study, however, were already colonized 
with B. producta prior to treatment, making it unlikely that B. producta alone was responsible for 
clearing the recurrent infections. Risk of recurrence was also negatively associated with E. lenta, 
which is part of the normal human gut microflora and can cause ulcerative colitis in humans.22 
Similarly to C. difficile, antibiotic treatment has been shown to increase the amount of E. lenta in 
the human gut microbiome.22,23 The results from the current study suggest that the relationship 
between recurrent CDI and certain commensal microorganisms is more complex than originally 
assumed and warrants further investigation. 
 Bacterial taxonomic groups also differed in relative abundance between case definitions. 
A major result was that the microbiomes of patients with community-acquired infections were 
more likely to contain taxa that are associated with healthy human gut microflora. Community-
acquired infections had a higher abundance of species in the genus Bacteroides, including B. 
fragilis, B. vulgatus, and B. helcogenes. Bacteroides species are commensal microorganisms that 
operate in the healthy human gastrointestinal tract.24 One study showed that patients with CDI 
were deficient in Bacteroides, while healthy controls maintained relatively high levels of species 
from this genus. Compared to hospital-acquired infections, community-acquired infections were 
also associated with higher levels of F. prausnitzii and crAssphage. F. prausnitzii is a member of 
Ruminococcaceae and is the most abundant species found in a healthy human gut microbiome.25 
CrAssphage, a lytic phage that targets Bacteroides, is one of the most commonly found 
bacteriophages in the human gut.26 Studies that sought to establish the association between 
bacteriophages and recurrent CDI risk and treatment found that individuals that suffer from 
recurrent CDI have lower levels of crAssphage than healthy fecal transplant donors.27  
 18 
The abundance of healthy commensal bacteria and bacteriophage in patients with 
community-acquired infections may be due to a number of reasons. First, community-acquired 
infections are usually less severe than hospital-acquired infections,4 which may indicate that the 
healthy gut microbiome is not as severely disturbed in these infections. Second, these patients 
have had little to no contact with health care leading up to their CDI and are more likely to be 
healthier than patients that have had extended hospital stays or repeated exposures to health care 
settings. This may also account for the differential expression of certain antibiotic resistance 
genes in patients with CDI. The microbiome of patients with hospital-acquired and healthcare-
associated infections were more likely to express genes resistant to fosfomycin or bacitracin and 
sulfonamide, respectively. Research has shown that ambulatory and hospitalized patients harbor 
a high prevalence of antibiotic resistant organisms, regardless of whether they actually took 
antibiotics.28  
Although there was a positive association between age and the risk for recurrence, the 
data from this study did not reveal any other associations between recurrence risk and other 
known factors for recurrence, including use of antibiotics and proton pump inhibitors.2,29 Failure 
to find significant associations between these variables may be due to the small sample size, 
which was a major limitation to this study. Stool samples were obtained from the Connecticut 
Emerging Infections Program, which is responsible for sending positive C. difficile stool samples 
to the CDC as part of a nationwide surveillance program. The sample size was therefore limited 
by the number of positive samples that were available for metagenomic analysis. Due to the 
prospective study design, individuals were enrolled in the study before we knew whether or not 
they would experience a recurrent infection. This, in keeping with the estimate that 
approximately 20% of all positive C. difficile cases eventually experience a recurrent infection, 
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resulted in the number of recurrent cases in the study to be limited to only 7 samples. 
Consequently, many of the statistical analyses performed in this study were underpowered. 
Future studies that seek to explore the association between the gut microbiome and the risk for 
recurrent CDI should aim to increase the overall sample size. 
 Potential missing and incomplete medical histories for the subjects enrolled in the study 
was another major limitation. The majority of stool samples included in the analysis were from 
individuals who lived outside the New Haven catchment area. Three subjects’ primary addresses 
were outside of Connecticut, while one subject moved out of state soon after their positive 
diagnosis. It is possible that individuals living outside of the New Haven catchment area received 
medical care from providers not in the Yale New Haven Health System (YNHHS). If so, it is not 
guaranteed that these medical visits were documented within the YNHHS Epic interface, and 
they may have been omitted during chart review. Consequently, information about patients’ 
medical histories, including administered antibiotics and comorbidities, may have been 
incomplete.  
 This study offers a preliminary analysis of the association between the risk of recurrence 
of Clostridioides difficile infection and the human gut microbiome and resistome. Increasing our 
understanding of the factors that influence the risk of recurrence can aid in future efforts to 
identify individuals with CDI who are most likely to go on and experience a recurrent episode, as 
well as inform possible treatment strategies for patients for whom standard antibiotic therapies 
are ineffective in clearing infection. Whole genome sequencing provides unique insights into the 
relationship between CDI and the human microbiome and antibiotic resistome that is not 
provided by traditional sequencing methods. This pilot study may operate as a stepping stone for 
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